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ORIGINAL ARTICLE
Brief maternal exposure of rats to the xenobiotics dibutyl
phthalate or diethylstilbestrol alters adult-type Leydig cell
development in male offspring
Richard Ivell1,2, Kee Heng1, Helen Nicholson3 and Ravinder Anand-Ivell2,4
Maternal exposure to estrogenic xenobiotics or phthalates has been implicated in the distortion of early male reproductive
development, referred to in humans as the testicular dysgenesis syndrome. It is not known, however, whether such early gestational
and/or lactational exposure can influence the later adult-type Leydig cell phenotype. In this study, Sprague–Dawley rats were exposed
to dibutyl phthalate (DBP; from gestational day (GD) 14.5 to postnatal day (PND) 6) or diethylstilbestrol (DES; from GD14.5 to
GD16.5) during a short gestational/lactational window, and male offspring subsequently analysed for various postnatal testicular
parameters. All offspring remained in good health throughout the study. Maternal xenobiotic treatment appeared to modify specific
Leydig cell gene expression inmale offspring, particularly during the dynamic phase ofmid-puberty, with serum INSL3 concentrations
showing that these compounds led to a faster attainment of peak values, and a modest acceleration of the pubertal trajectory. Part of
this effect appeared to be due to a treatment-specific impact on Leydig cell proliferation during puberty for both xenobiotics. Taken
together, these results support the notion that maternal exposure to certain xenobiotics can also influence the development of the
adult-type Leydig cell population, possibly through an effect on the Leydig stem cell population.
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INTRODUCTION
Maternal exposure of male rats to endocrine disrupting xenobiotics
such as dibutyl phthalate (DBP) or diethylstilbestrol (DES) is
known to impact on the early development of the male reproduct-
ive system.1 In particular, several of the symptoms of what in
humans has been termed the testicular dysgenesis syndrome (e.g.,
cryptorchidism and hypospadias) can be reproduced in some
strains of rats by such early maternal exposure.1,2 The principal
mechanism of action for these xenobiotics appears to be through
disturbance of fetal testis development, involving most testicular
cell types, including fetal Leydig cells and consequently, their pro-
duction of fetal androgens, as well as the fetal hormone INSL3. The
fetal population of Leydig cells is, however, quite discrete from
those Leydig cells which develop in the testis postnatally, and
which are presumed to differentiate de novo after birth from res-
ident peritubular mesenchymal stem cells. Recently, Travison
and colleagues3 suggested from data derived in the Massa-
chussetts Male Aging Study that adult circulating testosterone con-
centrations might also be determined by early, possibly maternal,
environmental factors, thereby adding reduced androgen produc-
tion in the aging male to the possible list of symptoms linked to the
testicular dysgenesis syndrome. This could imply either that endo-
crine disrupting xenobiotics might act directly on early Leydig stem
cells or that by acting upon other cells in the testis, or on other
components of the hypothalamo–pituitary–gonadal (HPG) axis,
they could indirectly impact on adult-type Leydig cell differenti-
ation and/or function. In support of this hypothesis, we recently
demonstrated that regenerating adult-type Leydig cells in the testes
of ethane dimethane sulfonate-treated rats indicated a disturbed
differentiation trajectory following an early and short in vivo expo-
sure to DBP and DES.4 Other studies have shown that similar early
xenobiotic exposure can indeed disrupt the onset of puberty in
female rats,5 hypothetically providing a rationale for understanding
the association in immigrant girls between early xenobiotic expo-
sures and precocious puberty.5
In the present study, pregnant Sprague–Dawley rats were given a
moderate dose of either DBP or DES (here used as an estrogenic
control) during a relatively short developmental window, such as
to cause a minimal disruptive effect on the male reproductive
system, though no other negative health outcomes. Both sub-
stances have been shown to impact on fetal Leydig cell function,
reducing both INSL3 and androgen expression by the fetus.2,6,7 We
have then assessed testis gene expression at three time points
before, during and after puberty in male offspring. The findings
indicate subtle but definite changes in the postnatal testicular
phenotype.
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MATERIALS AND METHODS
Ethics statement
All animal experimentation was approved by the University of
Adelaide Animal Ethics Committee (approval No. S-019-2007) and
adhered strictly to NIH guidelines.
Animals and treatments
Nine-week-old female Sprague–Dawley rats from Laboratory Animal
Services (University of Adelaide, Adelaide, Australia) were mated over-
night and checked the next morning for the presence of sperm in vaginal
smears. The morning when sperm were observed in the vaginal smears
was designated as gestation day 0.5 (GD0.5). The day when the pups
were delivered was designated as postnatal day 1 (PND1). Pregnant rats
and their offspring were maintained on soy-free standard AIN93G
rodent diet (Specialty Feeds, Glen Forrest, Australia) throughout the
experiment. Pregnant rats were divided into three groups, using rando-
mization of body weights to ensure equal weight distribution among
groups, and dosed as following (Figure 1): control group (n58): orally
gavaged with corn oil 1 ml kg21 body weight every second day from
GD14.5 to PND6 and subcutaneously injected with corn oil containing
0.5% ethanol on GD14.5 and GD16.5. DBP group (n59): orally gavaged
with DBP 500 mg kg21 body weight in corn oil every second day from
GD14.5 to PND6 and subcutaneously injected with corn oil containing
0.5% ethanol on GD14.5 and GD16.5. DES group (n512): orally
gavaged with corn oil 1 ml kg21 body weight every second day from
GD14.5 to PND6 and subcutaneously injected with DES 125 mg kg21
body weight in corn oil containing 0.5% ethanol on GD14.5 and GD16.5
only. On PND2, excess pups were culled, retaining 10 pups (female/male
ratio: ,1 : 1) per litter. On PND21, both male and female pups were
weaned and caged with their littermates of the same gender. Progeny
were culled by CO2 asphyxiation, as indicated, on PND10, 24 and 90
(Figure 1).
Left and right testes were collected for RNA preparation and RT-
PCR analysis, following snap-freezing in liquid nitrogen, and for
Bouin-fixation, paraffin-embedding and cell counting, respectively.
Only testes and blood from healthy animals, without gross testicular
dysgenesis, were included. Trunk blood was collected from the vena
cava at killing on days PND10, PND24 and PND 90. Peripheral blood
was additionally collected by tail vein bleeding on PND30, PND35,
PND40, PND45 and PND55. All samples were collected between 9:00
a.m. and 11:00 a.m.
Measurement of anogenital distance (AGD)
The AGD was measured from the base of the genitals to the centre of
the anal opening for all pups before culling on PND2 and PND10.
Pups were digitally photographed from the ventral aspect, including a
precise 1-mm scale in each picture as reference point. All images were
imported to the same computer and monitor for all measurements.
These were repeated twice several days apart by the same observer, who
was blinded to the treatment identities. The AGD for each animal was
the average of the two values obtained from the repeat measurements.
Vaginal opening in female offspring
Female offspring were checked daily from PND29 onwards for the
onset of sexual maturity as determined by the separation of the vaginal
membrane (i.e., vaginal opening).
RNA analysis
RNA was extracted from total testis tissue using the TRIzol reagent
(Life Technologies, Melbourne, Australia) and quality checked by
electrophoresis. After treatment with RNAse-free DNAse using the
TURBO DNA-free kit according to the manufacturer’s instructions
(Life Technologies), 3 mg total RNAper sample was reverse transcribed
using Superscript II (Life Technologies) reverse transcriptase primed
by oligo again according to the manufacturer’s instructions.
Quantitative RT-PCR (qRT-PCR) was carried out as previously
described8 using a Rotor-Gene 3000 (Corbett Research/Qiagen,
Mortlake, Australia) real-time PCR cycler, and the ExTaq Sybr-
Green pre-mix (Takara, Shiga, Japan), with oligonucleotide primers
and PCR conditions as listed in Table 1. Primer pairs were designed
using Primer 3 software to span at least one intron. For the luteinizing
hormone receptor gene (Lhcgr), primers were chosen specifically to
identify only full-length transcripts, since it is known that a number of
shorter non-functional Lhcgr transcripts are generated during Leydig
cell differentiation in the rat.9 Transcript levels were normalized
against the ribosomal protein transcript S27a.10 For each PCR reac-
tion, melt curves were calculated of final products which were subse-
quently checked by individual agarose gel electrophoresis for correct
size, followed by sequencing. Results of qRT-PCR were processed
using Q-gene96 software,11 and normalized gene expression (NE)
calculated according to the equation NE5(Eref)
CTref/(Etarget)
CTtarget,
where Etarget and Eref, and CTtarget and CTref are the PCR amplification
efficiencies and the threshold cycles (where the fluorescence curve
intersects the threshold) of the PCR amplification for the test tran-
script and S27a transcript, respectively.
Leydig cell counting
Leydig cell numbers were estimated from testis sections of PND24 and
PND90 rats using the fractionator and optical disector method.12,13
This method has been shown to be a precise approach to estimate the
total number of various testicular cell types within the whole testis.13
The procedure was carried out as previously described.14 Each testis
was cut into 10–15 slices of even thickness. These were laid out accord-
ing to their position in the testis. Three slices were randomly selected
and each exhaustively sectioned into 30-mm sections. The number of
30-mm sections from each testis slice was counted. Summation of the
number of sections from all selected testis slices is number of total
sections (f2). Again, using a randomly selected number, one section
was mounted, subjected to Periodic-Acid-Schiff staining withMayer’s
haematoxylin counterstaining, and cells were counted. Microscope
images were captured on Spot analysis software (Diagnostic
Instruments Inc., Sterling Heights, MI, USA) using a 3100 oil-free
Figure 1 Diagram to illustrate the treatment and sampling regimen applied (small
dots above the bar indicate approximate blood sampling times). The morphological
changes during pubertal Leydig cell differentiation (after16–18) are illustrated at
their corresponding times in the upper section of the figure. GD, gestational day;
PND, postnatal day; DBP, dibutyl phthalate; DES, diethylstilbestrol.
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objective (numerical aperture 0.95, for PND24 testes) or 340 oil-free
objective (numerical aperture 0.65, for PND90 testes) on an Olympus
BX-51 microscope attached with a Spot RT colour camera and
OptiScan motorized stage system. The OptiScan motorized stage was
programmed to move across the testis section in steps of 400 mm (for
PND24 testis) or 1 mm (for PND90 testis) in the x-axis, then 400 mm
(for PND24 testis) or 1 mm (for PND90 testis) in the y-axis, randomly
and systematically to traverse the entire testis section and ensure that
each cell has an equal chance of being counted. A 10310 cm acetate
counting frame was placed over the microscope image on the com-
puter screen. The section was imaged through the z-axis, initially
incorporating a guard zone of 2 mm. To avoid artefacts of the cutting
surface, no Leydig cells were counted within the guard zone. The
movement in the z-axis was measured by the attached microcator.
Leydig cells fulfilling the counting frame rule15 were counted as they
came into focus when the section was sectioned optically. Leydig cells
were recognized by their oval to spherical nucleus with a thin rim of
heterochromatin and prominent nucleolus.16–18 Finally, the entire tes-
tis cross-section was captured with 31.25 objective for determination
of the surface area of each testis section. The total number of Leydig
cells within the whole testis was estimated by the formula19:
N 5ˆQ31/f131/f231/f3, where Nˆ is the estimated total number, Q
is the number of Leydig cells counted in the disector, f1 is the fraction
of tissue (i.e., number of randomly selected slices/number of total
slices), f2 is the fraction of sections (i.e., total number of randomly
selected sections/number of total sections) and f3 is the sampling frac-
tion (i.e., S volume of dissectors/S volume of the entire testis section).
Immunoassays
Blood was collected into heparinized syringes and kept on ice for
30 min prior to preparing plasma, which was then stored at 220 uC
until analysis. Total testosterone was measured using a well validated
in-house time-resolved fluorescent immunoassay following cold eth-
anol extraction.20 INSL3 in blood was measured using a rodent-spe-
cific time-resolved fluorescent immunoassay, exactly as previously
described.21 Luteinising hormone (LH) was estimated using a com-
mercial rat LH ELISA kit (USCN Life, Wuhan, China), according to
the manufacturer’s protocol. The range of detection for this assay was
0.78 mIU ml21–50 mIU ml21. The assay was specific for natural or
recombinant rat LH and had no reported cross-reactivity with other
related proteins.
Statistical analysis
Comparisons between gene expression in control, DBP and DES
groups were made using ANOVA, followed by post hoc two-tailed t-
tests with the help of the Graphpad Prism version 5 package
(Graphpad Software, La Jolla, CA).
RESULTS
General effect of treatments
Administration of DBP to pregnant and lactating rats fromGD14.5 to
PND6 had no effect on maternal body weight or on the weights of
progeny born, measured at PND 21 (data not shown). All animals
appeared healthy throughout the experiment. All pregnant rats in
the control and DBP groups delivered exclusively live pups, though
Table 1 Oligonucleotide primers and conditions used for qRT-PCRs
Common name Gene Forward (59-39) Reverse (59-39) Size (bp)
Annealing
temperature (uC)
Insl3 Insl3 ctgctactgctgctcctggctcta gtggggacacagacccaaaa 372 67
11b-HSD1 Hsd11b1 ggtcaacgtgtccatcactctc catgatcctccttcctggattc 214 62
P450scc Cyp11a1 gtggcactcgtggggacag accccaatgggcctctggta 430 65
17b-HSD3 Hsd17b3 tggaaaagctacaggtcatctcag ggttgaaacagaataaggggtcag 455 60
LH receptor Lhcgr ctcatcgccctgtcttcctact tgcaaaagtctgcaaaggagag 481 62
17a-hydroxylase Cyp17a1 gcagaggtttgacttggatgtg gaggtatggatcggggatgtta 180 64
StAR Star ggaccttgaaaggctctgga tacagcgtacgcttacgaag 592 60
S27a Rps27a ccaggataaggaaggaattcctcctg ccagcaccacattcatcagaagg 297 64
Table 2 Offspring phenotype following treatments
Control DBP DES
No. of rats with live pups on PND1 8/8 9/9 10/12
No. of rats with stillbirth 0/8 0/9 2/12
No. pups/littera 13.6360.98 12.0060.82 9.0061.75b
Total no. pups born/treatment group 109 108 108
No. pups found dead on PND2 1 21 24
Pup survival rate (%) 99.08 80.56 77.78
Male offspring on PND24 with unilateral abdominal
cryptorchidism
0/8 (0%) 2/9 (22%) 1/9 (11%)
Male offspring with unilateral anorchia on PND24c 0/8 (0%) 3/9 (33%) 0/9 (0%)
Male offspring with unilateral testicular dysgenesis on
PND90d
1/16 (6%) 4/18 (22%) 1/11 (9%)
Total testicular dysgenesise 1/32 (3%) 9/36 (25%) 2/29 (7%)
Abbreviations: DBP, dibutyl phthalate; DES, diethylstilbestrol.
aMean6s.e.m.
b Including the two litters with still births (different from control and DBP groups; P,0.05). If the litters with still births are excluded, then the litter size becomes
10.8061.52 (not statistically different).
c Only one testis could be located on dissection.
d One testis was considerably smaller than the other by at least 35%.
e Sum of the three preceding categories.
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there was some subsequent perinatal mortality as well as testicular
dysgenesis (Table 2) for the DBP-treated offspring, as has been prev-
iously reported.2,22 Only those maternally DBP-treated animals which
showed no evidence of gross testicular dysgenesis were included in
subsequent analyses. Offspring gender ratio was not affected.
Administration of DES to rats at high doses has earlier been associated
with abortion of fetuses.23 For this reason, DES was given to pregnant
rats only on GD14.5 and GD16.5, and not at all during lactation.
Unlike the control and DBP-treated animals, the DES-treated rats
showed a small (9%; P,0.05) reduction in body weight at GD20.5
(data not shown). Two out of the initial 12 rats in this group had still-
births, whereby no live pups were born (Table 2). Excluding these two
rats, DES treatment led to a marginally smaller litter size (10.861.5;
mean6s.e.m.), compared to control (13.661.0) or DBP (12.060.8)
groups (not statistically significant). Once born, all pups grewwell and
healthily, with no differences in body weight between groups at
PND10 (data not shown). At PND21, both male and female DES pups
showed a 6%–7% increased body weight compared to control and
DBP groups (P,0.05; data not shown), which, however, did not per-
sist into adulthood. There was no evidence for any testicular dysgen-
esis among the male offspring maternally treated with DES (Table 2).
AGD
There were no between-group differences in AGD for both male (con-
trol: 2.1660.50 mm; mean6s.e.m.) and female (control 1.1660.42)
pups at PND2 (data not shown). However, at PND10, DBP-treated
male pups showed a reduced AGD compared to controls (Figure 2),
intermediate in size between male and female distances. DES treat-
ment also reduced male AGD at PND10. Female AGD showed no
effects of maternal treatment.
Vaginal opening
The day of vaginal opening was also continually monitored for the
female pups from PND29 as an indicator of female puberty. All treat-
ment groups showed no effect compared to controls (day 34.562.2;
mean6s.e.m.; data not shown), reinforcing the lack of effect of the
treatment paradigm on more general health parameters.
Effect of maternal DBP and DES treatments on testis parameters
Although relative testis size appeared to be modulated by the specific
maternal treatments (Figure 3b), with DBP-treated male offspring
having relatively smaller testes at PND10 and PND24, though larger
testes at PND90, this was less evident when assessing absolute testis
weights (Figure 3a). Then only the DES-treated animals at PND24
(i.e., at a very dynamic phase of puberty with accelerated testis growth)
showed evidence for increased testis weight.
Stereological analysis of the testes showed that total Leydig cell
numbers per testis were increased at PND24 only in the DES treatment
group (Figure 3f). By PND90, there were no notable differences
between both treatment groups and controls. Immunological analysis
of total testosterone and LH in peripheral blood showed no differences
for any treatment at any time point (Figure 3c and 3d), although a
trend towards higher values for LH was evident in the DES-treated
group at PND10 (Figure 3d). The ratio of T to LH within individuals
has been interpreted as a measure of total Leydig cell functional capa-
city.24,25 Although there was a major increase in this parameter
(mean6s.e.m. for all groups combined; P,0.001) between PND24
(0.03760.031; n518) and PND90 (0.44360.482; n518), as the
Leydig cells differentiate and the HPG axis attains its final mature
status (Figure 3e), therewere no differences between treatment groups
at all time points. Figure 3g indicates the ratio of circulating INSL3
(see below) to Leydig cell numbers per testis for those individual rats
where this was measured. As such, it therefore offers an indication of
individual Leydig cell functional capacity. Importantly, what this
figure shows is that in spite of increased Leydig cell numbers at
PND24, treatment does not appear to have altered their individual
capacity to generate INSL3. This is different at PND90, where in the
control group, Leydig cells appear to have reduced their individual
capacity to make INSL3, compared to PND24, though not in the two
treated groups.
The peptide hormone INSL3 is also considered a measure of Leydig
cell functional capacity.26 Analysis of circulating INSL3 (Figure 4)
showed that up to PND40 (i.e., during puberty), values for INSL3
tended to be higher in the DBP- and DES-treated groups compared
to controls, though subsequent to this time, particularly the DES-
treated group indicated lower circulating INSL3 compared to the
control group. Besides the increased total INSL3 production (area
under the curve) evident for the DBP treated group, there is also a
clear shift in themedian for each treatment group (Figure 4), with this
parameter being at PND42 for the controls, PND38 for the DBP-
treated group and PND37 for the DES-treated group. The median
was calculated as the value bisecting to 50% the area under the curve,
and then rounded to the nearest whole day.
Since the focus of this study was to assess any impact of maternal
treatment on adult-type Leydig cell function, analysis of Leydig cell-
specific gene expression was also undertaken. First of all expression
profiles for all seven transcripts being analysed was carried out on rat
testis samples collected throughout puberty (Figure 5) using quan-
titative real-time RT-PCR (qRT-PCR). This indicated that for each
gene, there was a different trajectory of expression, reflecting different
patterns of expression within the testis. For all gene transcripts,
PND24 appears to represent a particularly dynamic phase of Leydig
cell gene expression, corresponding in controls to the transition from
the immature to mature Leydig cell phenotype. In contrast, PND90
represents a stable adult phase, whereby any overexpression during
puberty and the establishment of the HPG axis appears now to be
subdued. Using these selected time points, the expression of these
genes was then measured by qRT-PCR, specifically comparing the
effects of maternal DBP and DES treatments versus vehicle controls
(Figure 6). For the Star, Hsd11b1 and Hsd17b3 gene products, there
was an effect of DBP treatment at PND10, and a trend also at this time
for the side-chain cleavage enzyme gene, Cyp11a1 (Figure 6). DES
treatment at this time point showed an effect only for the Star gene
Figure 2 Anogenital distance measured at PND10 (mean6s.e.m, n511–16) for
male and female pups maternally treated with DBP or DES. Horizontal bars and
asterisks indicate statistical differences (P,0.05). DBP, dibutyl phthalate; DES,
diethylstilbestrol. PND, postnatal day.
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transcript. At PND24, an effect was only evident for the full-length LH
receptor gene transcript (Lhcgr; Figure 6e), and only after DES treat-
ment, though trends were also observed for this treatment for Insl3
and Cyp11a1 gene transcripts. A trend was also evident upon DBP
treatment for Insl3 gene transcripts at PND24. There were no effects of
either treatment for any transcript at PND90, except for a trend to
higher values in the DES group for Insl3 (P50.06).
DISCUSSION
In this pilot study, and as in earlier studies,27–29 a dosing regimen for
both DES and DBP was chosen, which had as the primary objective
sufficient xenobiotic exposure to induce minimal though statistically
significant disruption of the classic end point of a reduced AGD in
male pups, though without obvious effects on general health para-
meters. Thus, any change observed in specific parameters is not attri-
butable to a general health deficit, but should be due to a specific
disruption of those features. For this reason also, the few maternally
DBP-treated offspring exhibiting gross testicular dysgenesis or
atrophy were also excluded, so as not to invoke effects which might
be the consequences of gross anatomical aberration. These criteria
were met and strongly supported by the generally low within- and
between-group variance in most parameters.
This study has focused on the long-term effects of maternal expo-
sure to DBP and DES in male rats and in particular on the phenotype
of adult-type Leydig cells in the intact testes. It does not aim therefore
to reassess the known acute effects of maternal exposure leading to
gross testicular dysgenesis (DBP), or to perinatal death (DES) that
have been previously reported.2,22,23 The observations relating to this
pathology are essentially in agreement with those described by other
authors.2,22,30 As measures of Leydig cell phenotype, we have assessed
specific Leydig cell numbers and gene expression shortly after ces-
sation of treatment at PND10, at a single dynamic time point during
their pubertal differentiation (PND24), and after the establishment of
adult endocrine stability at PND90. Additionally, we have assessed the
secretion into the circulation of the Leydig cell peptide hormone
INSL3, which we have shown is expressed constitutively, and accur-
ately reflects the numbers and/or differentiation status of Leydig cells
in humans and other species.26 Total circulating testosterone was also
measured, as was circulating LH. Both parameters were assessed only
for single time points per day (from 9:00 a.m. to 11:00 a.m.), and
therefore being pulsatile hormones, such measures are of statistical
value only for the sample population, where the T/LH ratio should
reflect the average capacity of Leydig cells for steroidogenesis.24,25
Although on PND24 at the beginning of puberty, there appeared to
be a trend for both DES and DBP groups to have lower individual
T/LH ratios compared to controls (data not shown), this did not reach
statistical significance (P50.2), and was definitely not maintained at
the later time point (PND90).
Although it is normal practice to assess testicular growth during
puberty, as for most other organs, as relative to whole body weight, for
the testis this may be spurious. Postnatal growth of the testis is largely
due to specific proliferation of Leydig and Sertoli cells, as well as of the
germinal epithelium, as a consequence of the activation of the hor-
mones of the HPG axis during puberty, and thus, is not necessarily
governed by the same factors as for the general postnatal growth of
other organs and tissues. Thus, the absolute testis weight for a cohort
of identically aged rats appears to be a better assessment of the impact
of maternal exposure to xenobiotics, compared to the relative testis
weight. Importantly, these results indicate an effect on testis weight
Figure 3 Absolute (a) and relative (b) testis weights at PND10, PND24 and PND90 for control, maternally DBP-treated and maternally DES-treated rats, as indicated
(mean6s.e.m.; n58–16). Circulating testosterone (c) and LH (d) concentrations for the same treatment groups as above (mean6s.e.m.; n56). (e) T/LH ratio for
individual rats as a measure of Leydig cell capacity. (f) Absolute LC numbers per testis stereologically counted using the optical disector method at PND24 and PND90
for control, maternally DBP-treated, and maternally DES-treated rats (mean6s.e.m.; n53–5). (g) The quotient of circulating INSL3 concentration relative to estimated
LC number per testis within individual animals (mean6s.e.m.; n53–5), as an indicator of individual Leydig cell capacity. Unless otherwise indicated, asterisks show
statistical differences (P,0.05). LC, Leydig cell; LH, luteinizing hormone; PND, postnatal day; T, testosterone.
Figure 4 Circulating serum INSL3 concentration in control, maternally DBP-
treated and maternally DES-treated rats at different ages, as indicated (mean6
s.e.m.; n56). Calculated medians are indicated by vertical arrows. Asterisks
indicate statistical differences (P,0.05). DBP, dibutylphthalate; DES, diethylstil-
bestrol; PND, postnatal day.
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only of gestational DES treatment, and only at PND24, the most
dynamic phase of testicular growth. This observation is also in full agree-
ment with the estimate of total Leydig cell numbers per testis, as well as
with the secretion profiles for the peptide hormone INSL3. Leydig cell
numbers were close to those previously reported by Zirkin and Ewing31
and Hardy et al.17 Close inspection of the testicular histology (data not
shown) indicated that the increase in Leydig cell numbers did not appear
to be associated with any kind of focal hyperplasia as has been reported
for the fetal testis under DBP treatment.32 Nor was there any evidence for
focal atrophy in any of the testes examined, which, however, did exclude
any of the grossly dysgenic testes resulting frommaternal DBP treatment.
Taken together, all of these data strongly suggest that particularly mater-
nal estrogen exposure serves to accelerate postnatal Leydig cell differenti-
ation and proliferation, resulting in an advance in the median value of
INSL3 secretion from PND42 (control) to PND37 (DES treatment). The
values for circulating LH at PND10 and PND24 would support this
argument, suggesting an impact of gestational xenoestrogen exposure
also on the development of the HPG axis. In contrast, maternal DBP
treatment has little if any effect on either testis growth or Leydig cell
numbers, although the circulating INSL3 profiles do suggest modest
acceleration in Leydig cell differentiation, leading to earlier and higher
circulating levels of INSL3, for example, at PND35, and which is reflected
in the trends to increased Insl3mRNA at PND24. The lack of xenobiotic
impact on adult testosterone level is not surprising given its high within-
animal fluctuation, and has been reported previously.29
Looking at specific testicular gene expression, it is also evident that
maternal DBP treatment is having a similar positive impact on those
gene transcripts involved in the first stages of the establishment of
steroidogenesis, namely, Cyp11a1, Hsd17b3 and Star, though only at
PND10. Interestingly, transcripts for the full-length LH receptor
(Lhcgr) as well as for the side-chain cleavage enzyme (Cyp11a1), which
are both relatively early-intermediate markers of Leydig cell differenti-
ation, are both reduced for the DES-treated group at PND24. Note
that Insl3 is a relatively latemarker of Leydig cell differentiation. Taken
together, these observations again support the notion that early estro-
genic exposure is causing a temporal disruption of normal Leydig cell
proliferation and differentiation, with early progenitor Leydig cells
proliferating longer in an immature state (PND10), but then dif-
ferentiating faster (PND24) to complete puberty somewhat earlier
(median circulating INSL3 at PND37). The DBP effects are probably
comparable to these, or intermediate between DES and control
groups, though less intense, leading to few differences in the measured
parameters compared to controls. These results are similar to those
recently reported for maternal bisphenol A exposure, which appears
to have comparable estrogenic effects on adult-type Leydig cell dif-
ferentiation.33 There is also a good correlation between the findings
reported here and our recent study on the influence of DBP and
DES upon adult-type Leydig cell regeneration following ethane
dimethane sulfonate ablation,4 where also the kinetics of Leydig cell
differentiation was modulated by these xenobiotics.
This study has also highlighted the value of measuring circulating
INSL3 during puberty, by emphasizing what has earlier been referred
to as the ‘overshoot’ effect.21 As Leydig cells differentiate during
puberty, concomitant with the large and initially not well regulated
pulses of LH from the pituitary, they initially give rise to an over-
production of INSL3 as a measure of Leydig cell differentiation status.
Unlike testosterone, whose enzymatic production is acutely regulated
by feedback from the pituitary, INSL3 is constitutively expressed.26
Circulating testosterone, therefore, does not reveal such an overshoot
effect, but once a maximum is attained, the testosterone level is held
more or less constant by acute feedback regulation from theHPG axis.
Following the overshoot at around day 40, circulating INSL3 produc-
tion, and presumably Leydig cell activity, relaxes to yield stable and
considerably lower adult levels by about days 60–90, when Leydig cell
differentiation status has become regularized at a lower level as a
consequence of chronic HPG control. This is reflected also in the
Figure 5 Transcript profiles measured for specific genes by qRT-PCR in RNA extracted from intact testes of untreated Sprague–Dawley rats culled at the days
indicated (mean6s.e.m.; n54). All transcripts are expressed normalized against the housekeeping control transcript for ribosomal protein S27a.
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reduced measure of INSL3 per individual Leydig cell. Interestingly,
although this cannot be statistically supported, the results suggest that
at PND90, both DBP and DES treatments lead to a modest reduction
in LH and in total Leydig cell numbers per testis, which then appear to
maintain their pubertal level of INSL3 production per individual cell.
The results of this study suggest that there may indeed be long-term
though subtle consequences of maternal xenobiotic exposure for adult
testis function, particularly during puberty and the establishment of
the stable adult phenotype. Obviously, more detail is needed in order
to explore precisely themechanisms by which these long-term changes
are achieved.
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